Myeloid Working Group

The UF Myeloid Working Group is formed by over a dozen basic science, translational and clinical research teams focused on the study and eradication of myeloid neoplastic diseases such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), chronic myeloid leukemia (CML), and other myeloproliferative neoplasms (MPNs).

The mission of the Myeloid Working Group is to catalyze myeloid neoplasia research through hypothesis-driven, collaborative and translational clinical trials. The group takes strength from the breadth and depth of team leaders, and the University of Florida’s investments in clinical translational science, including next generation sequencing shared resource, proteomics core, modeling laboratories,  biostatistics and quantitative sciences shared resourse, medicinal chemistry, toxicology and pharmacology, GMP production facilities, clinical research office, and an NIH supported UF Clinical and Translational Science Institute that provides important resources for moving ideas into clinically impactful clinical trials.

For more information, contact Christopher R. Cogle, M.D. at christopher.cogle@medicine.ufl.edu or Jatinder Lamba, Ph.D. at JLamba@cop.ufl.edu.